This listing of claims will replace all prior versions, and listings, of claims in the application:

Please amend claims 60, 70, 74, 81, 91, 95, 103 and 104 as follows:

Listing of Claims:

Claims1-59 (Canceled)

Claim 60 (currently amended): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising administering to a subject in need of prostaglandin at least one NO producing agent at a low dose, which does not produce significant systemic side effects, but which decreases pain associated with prostaglandin use**, wherein said low dose of said at least one NO producing agent is a unit dose of about 0.88 µmole or less.**

Claim 61 (previously added): The method of claim 60 wherein the subject is male.

Claim 62 (previously added): The method of claim 60 wherein the subject is female.

Claim 63 (cancelled).

Claim 64 (previously added): The method of claim 60 wherein the NO producing agent inhibits a cyclic nucleotide phosphodiesterase.

Claim 65 (previously added): The method of claim 64 wherein the cyclic nucleotide phosphodiesterase is PDE3.

Claim 66 (previously added): The method of claim 60 wherein the NO producing agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal

administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.

Claim 67 (previously added): The method of claim 60 wherein two agents are administered.

Claim 68 (previously added): The method of claim 60 wherein the NO producing agent is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

Claim 69 (previously added): The method of claim 60 wherein the NO producing agent is glyceryl trinitrate.

Claim 70 (currently amended): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising administering to a subject in need of prostaglandin at least one agent at a low dose, which does not produce significant systemic side effects, but which augments action of cGMP so that pain associated with prostaglandin use sensed by nociceptive tissue in close proximity to engorgeable tissue is decreased, **wherein said low dose of said at least one agent is a unit dose of about 0.88 μmole or less.**

Claim 71 (previously added): The method of claim 70 wherein the subject is male.

Claim 72 (previously added): The method of claim 70 wherein the subject is female.

Claim 73 (cancelled):

Claim 74 (currently amended): The method of claim 70 wherein the agent augments action of cGMP by generating CO **or NO**.

Claim 75 (previously added): The method of claim 70 wherein the agent inhibits a cyclic nucleotide phosphodiesterase.

Claim 76 (previously added): The method of claim 75 wherein the cyclic nucleotide phosphodiesterase is PDE3.

Claim 77 (previously added): The method of claim 70 wherein the agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.

Claim 78 (previously added): The method of claim 70 wherein two agents are administered.

Claim 79 (previously added): The method of claim 70 wherein said agent which augments action of cGMP is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

Claim 80 (previously added): The method of claim 70 wherein the agent which augments action of cGMP is glyceryl trinitrate.

Claim 81 (currently amended): A method of decreasing pain associated with the use of prostaglandin in a subject in need thereof, said method comprising:
administering a therapeutically effective amount of prostaglandin and at least one NO producing agent in an amount effective to decrease pain associated with the use of said prostaglandin, wherein said at least one NO producing agent is in a unit dose of ~~0.67~~ **0.88** μmole or less.

Claim 82 (previously added): The method of claims 81, wherein the subject is male.

Claim 83 (previously added): The method of claim 81, wherein the subject is female.

Claim 84 (previously added): The method of claim 81, wherein the NO producing agent augments action of cAMP in smooth muscle and reduces action of cAMP in nociceptive tissue.

Claim 85 (previously added): The method of claim 81, wherein the NO producing agent inhibits a cyclic nucleotide phosphodiesterase.

Claim 86 (previously added): The method of claim 85, wherein the cyclic nucleotide phosphodiesterase is PDE3.

Claim 87 (previously added): The method of claim 81, wherein the NO producing agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.

Claim 88 (previously added): The method of claim 81, wherein two agents are administered.

Claim 89 (previously added): The method of claim 81, wherein the NO producing agent is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

Claim 90 (previously added): The method of claim 89, wherein the NO producing agent is glyceryl trinitrate.

Claim 91 (currently amended) A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction, said method comprising: administering to a subject in need of prostaglandin at least one agent which augments action of cGMP in an amount effective to decrease pain associated with the use of said prostaglandin, wherein said at least one agent which augments action of cGMP is in a unit dose of is in a unit dose of ~~0.67~~ **0.88** μmole or less.

Claim 92 (previously added): The method of claim 91, wherein the subject is male.

Claim 93 (previously added): The method of claim 91, wherein the subject is female.

Claim 94 (previously added): The method of claim 91, wherein the agent augments action of cAMP in smooth muscle and reduces action of cAMP in nociceptive tissue.

Claim 95 (currently amended): The method of claim 91, wherein the agent augments action of cGMP by generating CO **or NO**.

Claim 96 (previously added): The method of claim 91, wherein the agent inhibits a cyclic nucleotide phosphodiesterase.

Claim 97 (previously added): The method of claim 96, wherein the cyclic nucleotide phosphodiesterase is PDE3.

Claim 98 (previously added): The method of claim 91, wherein the agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.

Claim 99 (previously added): The method of claim 91, wherein two agents are administered.

Claim 100 (previously added): The method of claim 91, wherein said agent which augments action of cGMP is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

Claim 101 (previously added): The method of claim 100, wherein the agent which augments action of cGMP is glyceryl trinitrate.

Claim 102 (previously added): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction, said method comprising: administering to a subject in need of prostaglandin at least one agent which augments action of cGMP in an amount effective to decrease pain associated with the use of said prostaglandin, wherein said at least one agent which augments action of cGMP is in a unit dose of 200 μg or less.

Claim 103 (currently amended): A method for decreasing pain associated with the presence of prostaglandin, said method comprising:
administering at least one NO producing agent in an amount effective to decrease pain resulting from the presence of prostaglandin, wherein said amount of at least one NO **agent** producing is in a unit dose of 200 μg or less.

H7

Claim 104 (currently amended): A method for decreasing pain associated with the presence of prostaglandin, said method comprising:
administering at least one NO producing agent in an amount effective to decrease pain resulting from the presence of prostaglandin, wherein said amount of at least one NO producing agent is in a unit dose of ~~0.67~~ **0.88** or less.

Claim 105 (previously added): A method of decreasing pain associated with the use of prostaglandin in a subject in need thereof, said method comprising:
administering a therapeutically effective amount of prostaglandin and at least one NO producing agent in an amount effective to decrease pain associated with the use of said prostaglandin, wherein said at least one NO producing agent is in a unit dose of 200 μg or less.

Claim 106 (previously added): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction, said method comprising:
administering to a male subject in need of prostaglandin at least one agent which augments action of cGMP in an amount effective to decrease pain associated with the use of said prostaglandin, wherein said at least one agent which augments action of cGMP is in a unit dose of 200 μg or less.

Claim 107 (new): The method of claim 103, wherein said at least one NO producing agent is SNP.

H8

Claim 108 (new): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising:

administering to a subject a prostaglandin with at least one NO producing agent at a low dose, which does not produce significant systemic side effects, but which decreases pain associated with prostaglandin use, wherein the mole ratio of prostaglandin to said at least one NO producing agent is about 1 to about 12.

Claim 109 (new): The method of claim 108, wherein the mole ratio of prostaglandin to said at least one NO producing agent is about 1 to about 6.

Claim 110 (new): The method of claim 108, wherein the mole ratio of prostaglandin to said at least one NO producing agent is about 1 to about 4.

Claim 111 (new): The method of claim 108, wherein the mole ratio of prostaglandin to said at least one NO producing agent is about 1 to about 3.